-DOCSTART- -X- O
SiRNAs -X- _ O
exert -X- _ O
their -X- _ O
biological -X- _ O
effect -X- _ O
by -X- _ O
guiding -X- _ O
the -X- _ O
degradation -X- _ O
of -X- _ O
their -X- _ O
cognate -X- _ O
mRNA -X- _ O
sequence -X- _ O
, -X- _ O
thereby -X- _ O
shutting -X- _ O
down -X- _ O
the -X- _ O
corresponding -X- _ O
protein -X- _ O
production -X- _ O
( -X- _ O
gene -X- _ O
silencing -X- _ O
by -X- _ O
RNA -X- _ O
interference -X- _ O
or -X- _ O
RNAi -X- _ O
) -X- _ O
. -X- _ O
Due -X- _ O
to -X- _ O
this -X- _ O
property -X- _ O
, -X- _ O
siRNAs -X- _ O
are -X- _ O
emerging -X- _ O
as -X- _ O
promising -X- _ O
therapeutic -X- _ O
agents -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
inherited -X- _ O
and -X- _ O
acquired -X- _ O
diseases -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
research -X- _ O
tools -X- _ O
for -X- _ O
the -X- _ O
elucidation -X- _ O
of -X- _ O
gene -X- _ O
function -X- _ O
in -X- _ O
both -X- _ O
health -X- _ O
and -X- _ O
disease. -X- _ O
Because -X- _ O
of -X- _ O
their -X- _ O
lethality -X- _ O
and -X- _ O
prevalence -X- _ O
, -X- _ O
lung -X- _ B-Outcome
diseases -X- _ I-Outcome
have -X- _ I-Outcome
attracted -X- _ I-Outcome
particular -X- _ I-Outcome
attention -X- _ I-Outcome
as -X- _ I-Outcome
targets -X- _ I-Outcome
of -X- _ I-Outcome
siRNA-mediated -X- _ I-Outcome
cures. -X- _ I-Outcome
In -X- _ I-Outcome
addition -X- _ I-Outcome
, -X- _ I-Outcome
lung -X- _ I-Outcome
is -X- _ I-Outcome
accessible -X- _ I-Outcome
to -X- _ I-Outcome
therapeutic -X- _ I-Outcome
agents -X- _ I-Outcome
via -X- _ I-Outcome
multiple -X- _ I-Outcome
routes -X- _ I-Outcome
, -X- _ I-Outcome
e.g. -X- _ I-Outcome
, -X- _ I-Outcome
through -X- _ I-Outcome
the -X- _ I-Outcome
nose -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
mouth -X- _ I-Outcome
, -X- _ I-Outcome
thus -X- _ I-Outcome
obviating -X- _ I-Outcome
the -X- _ I-Outcome
need -X- _ I-Outcome
for -X- _ I-Outcome
targeting -X- _ I-Outcome
and -X- _ I-Outcome
making -X- _ I-Outcome
it -X- _ I-Outcome
an -X- _ I-Outcome
appealing -X- _ I-Outcome
target -X- _ I-Outcome
for -X- _ I-Outcome
RNAi-based -X- _ I-Outcome
therapeutic -X- _ I-Outcome
strategies. -X- _ I-Outcome
The -X- _ O
clinical -X- _ O
success -X- _ O
of -X- _ O
siRNA-mediated -X- _ B-Intervention
interventions -X- _ I-Intervention
critically -X- _ O
depends -X- _ O
upon -X- _ O
the -X- _ O
safety -X- _ O
and -X- _ O
efficacy -X- _ O
of -X- _ O
the -X- _ O
delivery -X- _ O
methods -X- _ O
and -X- _ O
agents. -X- _ O
Delivery -X- _ B-Intervention
of -X- _ I-Intervention
siRNAs -X- _ I-Intervention
relevant -X- _ I-Intervention
to -X- _ I-Intervention
lung -X- _ I-Intervention
diseases -X- _ I-Intervention
has -X- _ O
been -X- _ O
attempted -X- _ O
through -X- _ O
multiple -X- _ O
routes -X- _ O
and -X- _ O
using -X- _ O
various -X- _ O
carriers -X- _ O
in -X- _ O
animal -X- _ B-Patient
models. -X- _ I-Patient
This -X- _ O
review -X- _ O
focuses -X- _ O
on -X- _ O
the -X- _ O
recent -X- _ O
progress -X- _ O
in -X- _ O
non-viral -X- _ O
delivery -X- _ O
of -X- _ O
siRNAs -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
lung -X- _ O
diseases -X- _ O
, -X- _ O
particularly -X- _ O
infectious -X- _ O
diseases. -X- _ O
The -X- _ O
rapid -X- _ O
progress -X- _ O
will -X- _ O
put -X- _ O
siRNA-based -X- _ O
therapeutics -X- _ O
on -X- _ O
fast -X- _ O
track -X- _ O
to -X- _ O
the -X- _ O
clinic -X- _ O
. -X- _ O

